You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Chinese patent medicine Fei-Liu-Ping ointment as an adjunctive treatment for non-small cell lung cancer: protocol for a systematic review

Article Text

Article menu

Download PDFPDF

XML
Oncology
Protocol
Chinese patent medicine Fei-Liu-Ping ointment as an adjunctive treatment for non-small cell lung cancer: protocol for a systematic review
  1. Honggang Zheng1,
  2. Shulin He1,2,
  3. Rui Liu1,
  4. Xinyao Xu1,2,
  5. Tao Xu1,
  6. Shuntai Chen1,2,
  7. Qiujun Guo1,2,
  8. Yebo Gao1,2,
  9. Baojin Hua1
  1. 1Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
  2. 2Beijing University of Chinese Medicine, Beijing, China
  1. Correspondence to Professor Honggang Zheng; honggangzheng{at}126.com

Abstract

Introduction Fei-Liu-Ping ointment has been widely applied as adjunctive drug in the treatment of non-small cell lung cancer (NSCLC). However, there has been no systematic review of research findings regarding the efficacy of this treatment. Here, we provide a protocol for assessing the effectiveness and safety of Fei-Liu-Ping ointment in the treatment of NSCLC.

Methods and analysis The electronic databases to be searched will include MEDLINE (PubMed), Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, Excerpt Medica Database (EMBASE), China National Knowledge Infrastructure (CNKI), China Scientific Journal Database (VIP), Wanfang Database and Chinese Biomedical Literature Database (CBM). Papers in English or Chinese published from inception to 2016 will be included without any restrictions. We will conduct a meta-analysis of randomised controlled trial if possible. The therapeutic effects according to the standard for treatment of solid tumours by the WHO and the quality of life as evaluated by Karnofsky score and weight will be applied as the primary outcomes. We will also evaluate the data synthesis and risk of bias using Review Manager 5.3 software.

Dissemination The results of this review will offer implications for the use of Fei-Liu-Ping ointment as an adjunctive treatment for NSCLC. This knowledge will inform recommendations by surgeons and researchers who are interested in the treatment of NSCLC. The results of this systematic review will be disseminated through presentation at a conference and publication of the data in a peer-reviewed journal.

Trial registration number PROSPERO CRD42016036911.

  • Non small cell lung cancer
  • FLP ointment
  • systematic review
  • protocol
  • Chinese patent medicine

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/bmjopen-2016-015045

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • HZ and SH are co-first authors.

    • Contributors HZ and SH contributed to the conception of the study. HZ and SH wrote the draft of manuscript, and was revised by XX, TX, SC, QG, YG and BH. The search strategy was developed by all of the authors, HZ and SH will search, extract data, assess the risk of bias, and complete the data synthesis. RL will arbitrate in case of disagreement and ensure the absence of errors. All authors approved the publication of the protocol.

    • Funding This work was supported by the National Natural Science Foundation of China (grant numbers 81273718 and 81102719).

    • Disclaimer The funders had no influence on the study design, data collection and analysis, as well as the right to publish.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement The findings of this systematic review will be disseminated via peer-reviewed publications and conference presentations. Please contact the corresponding author for further information if the unpublished data from this study are available.